icon-folder.gif   Conference Reports for NATAP  
 
  HIV Glasgow 2026
8-11 November
Back grey_arrow_rt.gif
 
 
 
Evaluation of Weight at Week 48 in a Phase 3 Study in Adults Initiating Treatment for HIV-1 With Doravirine/Islatravir (100 mg/0.25 mg) versus Bictegravir/Emtricitabine/Tenofovir Alafenamide
 
 
  Glasgow 2026 Nov 8-11

1109261copy

1109262copy

1109263copy

1109264copy

1109265copy

1109266copy

1109267copy

1109268copy

1109269copy

11092610copy

11092611copy

11092612copy